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1. Introduction
Emergence and re-surgence of vector-borne diseases still constitute an important threat to
human health in the 21st century, causing over a million death and considerable mortality
and morbidity worldwide. Vector-borne diseases are linked to the environment by the ecol‐
ogy of the vectors and of their hosts, including humans. In the recent decades, climate
change is a global phenomenon which has greatly influenced the emergence and resurgence
of several infectious diseases such as malaria, dengue fever, plague, filariasis, trypanosomia‐
sis, leishmaniasis and arbo-viral diseases, particularly yellow fever. Indeed, arbo-viruses
will represent a threat for the coming century too. The resource constrained developing
countries are the foremost sufferer and the major victims of several vector-borne diseases
[1], including yellow fever.
Yellow fever (YF) is one of the great infectious scourges of humankind. It is a zoonosis in‐
digenous to some tropical regions of South America and Africa which has caused numerous
epidemics with high mortality rates throughout history [2]. Approximately 200,000 cases of
YF occur annually, resulting in about 30 000 deaths; 90% of cases occur in Africa. Large epi‐
demics, with over 100,000 cases, have been recorded repeatedly in Sub-Saharan Africa, and
multiple outbreaks have occurred in the Americas. The virus has never appeared in Asia or
in the Indian subcontinent [3].
YFV is endemically transmitted in forests and savannas of South America and Africa, peri‐
odically emerging from enzootic cycles to cause epidemics of hemorrhagic fever [2],with re‐
ported fatality rates ranging from 20% to 80% due to two principal syndromes: YEL-AND
(yellow-fever associated neurologic disease, which includes encephalitis, myelitis or myelo-
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encephalitis [ADEM]), and YEL-AVD (yellow-fever associated viscerotropic disease, which
usually involves multi-organ failure including liver, renal and circulatory failure) [4].
Although YF has undoubtedly been endemic in tropical Africa for thousands of years, it was
only after the arrival of the European migrants in the New World at the end of the fifteenth
century that this scourge emerged in the form of devastating epidemics. The term ‘vomito‐
negro’ was used in those days to describe clinical aspects of this pathological condition, be‐
cause death was frequently preceded by black vomit or by partially digested blood. Other
terms used to designate yellow fever included ‘Yellow Jack’ and ‘Safran scourge,’ with refer‐
ence to the jaundice observed in many patients [5].
Griffin Hughes was the first to use the term “yellow fever” to describe the disease in his
book in 1750 [6]. At different stages of human development, YF has caused untold hardship
and indescribable misery among different populations in the Americas, Europe, and Africa.
Hundreds of thousands of people have been affected by the disease throughout ages among
which tens of thousands have died. YF brought economic disaster in its wake, constituting a
stumbling block to development too [7].
YF is known for bringing on a characteristic yellow tinge to the eyes and skin, and for the
terrible “black vomit” caused by bleeding into the stomach [8,9]. It was one of the most
feared lethal diseases before the development of effective vaccine. Today the disease still af‐
fects as many as 200,000 persons annually in the tropical regions of Africa and South Ameri‐
ca, and poses a significant hazard to unvaccinated travellers to these areas [10]. Recent
increases in the density and distribution of the urban mosquito vector, Ae. aegypti, as well as
the rise in air travel has increased the risk of introduction and spread of yellow fever to
North and Central America, the Caribbean and Asia [10].
In East Africa, yellow fever remains as a disease of increasing epidemic risk. The most recent
yellow fever outbreak in the region was reported by the WHO in the late 2010 and included
the first human cases reported in Uganda in almost 50 years [11]. Prior to this, outbreaks oc‐
curred in Sudan (2003 and 2005) and were the first reports of yellow fever from that country
in approximately 50 years. These events were preceded by the first outbreak ever reported
in Kenya (1992–1993), which were the first reported human cases in East Africa for close to
25 years [11].
Over the last 20 years the number of yellow fever epidemics has risen and more countries
are reporting cases. Mosquito numbers and habitats are increasing. Nevertheless, in both Af‐
rica and the Americas, there is a large susceptible, unvaccinated population. Changes in the
world's environment, such as deforestation and urbanization, have increased contact with
the mosquito/virus. Widespread international travel plays an important role in spreading
the disease. The priorities are vaccination of exposed populations, improved surveillance
and epidemic preparedness [12]. During the 20th century yellow fever has reemerged as a
cause of human suffering. The recent epidemics are clearly indicating the vulnerability and
potentiality of the YF as a global public health threat in the changing environment. In this
context, the present chapter becomes more significant and pertains.
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2. Global public health impact
The virus is endemic in tropical areas of Africa and Latin America, with a combined popula‐
tion of over 900 million people [13]. During the past decade, official reports of YF incidence
(50-120 cases a year from South America and 200–1200 cases a year from Africa) probably
underestimate the true number of cases. Many cases of jaundice and fever (a surveillance
definition of yellow fever) are not assessed, unexplained deaths go unreported, symptoms
suggest alternative diagnoses, and, in some countries, surveillance systems for yellow fever
are not in place [14]. The case-fatality rate ranges from 20% to 50% and is partly dependent
on case recognition and testing practices [15,16]. The continued presence and epidemic po‐
tential of yellow fever virus make it a global health threat. The growth of international travel
to endemic areas annually has increased the number of travelers potentially exposed to the
virus and consequently it has increased the risk of introduction into other new areas where
competent vectors are present [10].
3. A brief history of YF
The cause of YF was unknown, but it was thought to be contracted either by coming into
contact with “effluvia” from those stricken by the disease or with fomites such as cloth‐
ing, sheets, and other articles that patients had used. Fear of contracting the contagion led
people to shun their neighbours and friends and even to abandon loved ones. “It just tore
society apart” [17]. Known today to be spread by infected mosquitoes, yellow fever was
long believed to be a miasmatic disease originating from rotten vegetable matter and oth‐
er  putrefying filth,  and most  believed the fever to be contagious.  There were many de‐
bates regarding the agent that caused YF and Carlos Findlay was the first to suggest that
mosquitoes transmitted the disease [8,9]. Text box 1 indicates some of the key milestones
in the history of YF [18].
The earliest description of yellow fever is found in a Mayan manuscript in 1648, but by ge‐
nome sequence analysis it appears that yellow fever virus evolved from other mosquito-
borne viruses about 3000 years ago [19]. Yellow fever originated in Africa and in the 1500s
yellow fever virus was probably introduced into the New World via ships carrying slaves
from West Africa. Epidemics soon became common in the coastal communities of South and
Central America and along the southern and eastern seaboard of North America as far north
as Boston. Between 1668 and 1893, there were more than 135 epidemics in the USA [17].
Large epidemics occurred throughout the 18th and 19th centuries in the Caribbean islands,
the United States, Africa, Europe, West Indies, and South America.
4. Geographical distribution
YF is present in both the rural and urban tropical areas of 45 endemic countries in Africa
and Latin America, with a potential combined population of over 900 million individuals
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[20]. The vast majority of cases and deaths take place in sub-Saharan Africa, where yellow
fever is a major public health problem occurring in epidemic patterns. Africa also experien‐
ces periodic yet unpredictable outbreaks of urban yellow fever. Thirty-two African countries
are now considered at risk of yellow fever, with a total population of 610 million people,
among which more than 219 million live in urban settings [21]. The countries in Africa and
the Americas to be at the risk of yellow fever is given in text box 2 [22].
Year Description of events
1648 An epidemic of probable yellow fever erupts in the Yucatan Peninsula (Mexico)
1750 Griffin Hughes was the first to use the term “ yellow fever ” to describe the disease in his book
1793 An epidemic in Philadelphia kills about 10% of the population and sparks debate between ‘‘contagionists’’
and ‘‘anti-contagionists.’’
1802 StubbinsFfirth, a Philadelphia medical student, begins self-experiments to disprove the theory of contagion.
1854 Luis Daniel Beauperthuy of Venezuela suggests that a mosquito might transmit yellow fever.
1881 Carlos J. Finlay of Havana publishes his hypothesis that a specific mosquito (Cubex cubensis now Aedes
aegypti) might transmit yellow fever.
1880s Yellow fever in Panama kills tens of thousands of French workers, causing Ferdinand DeLesseps to abandon
his attempt to build a canal across the isthmus.
1901 The Reed Commission publishes its definitive proof of the mosquito hypothesis based on the data obtained
at Camp Lazear.
1902 William Crawford Gorgas supervises on the eradication of yellow fever from Havana by controlling Ae.
aegypti.
1916 The Rockefeller Foundation begins its commitment to eradicate yellow fever.
1925 The Rockefeller Foundation opens a laboratory in Yaba, Nigeria, to investigate the etiology of yellow fever.
1927 The causative agent of YF disease, YFV, was first isolated from a Ghanaian patient named Asibi
1930 Max Theiler demonstrates that white mice are susceptible to yellow fever by intracerebral inoculation,
which leads to a ‘‘mouse protection test’’ for seroepidemiologic studies and to an effective vaccine.
1933 Fred L. Soper and colleagues report an outbreak of yellow fever in a rural area of Brazil in which Ae.
aegypti was not present, suggesting other vectors.
1937 Large-scale immunizations with the 17-D yellow fever vaccine are begun.
1940s Due to mass vaccination campaigns and efforts to remove Ae. aegypti breeding sites, urban YF was
dramatically controlled in Africa, particularly in French speaking West African countries
1951 Theiler receives the Nobel Prize for his work that led to the discovery of the 17D vaccine.
2002 The World Health Organization estimates that yellow fever affects each year up to 200,000 persons with
up to 30,000 deaths.
Text Box 1. Key Milestones in the History of Yellow Fever (Bryan et al., 2004) [18]
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Africa
West Africa Benin, Burkina Faso, Cape Verde, Coˆ te d’Ivoire, Equatorial Guinea, Gambia, Ghana, Guinea,
Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra
Leone, Togo
Central Africa Angola, Burundi, Cameroon, Central African Republic, Chad, Democratic Republic of the Congo,
Gabon, Rwanda
East Africa Ethiopia, Kenya, Somalia, Sudan, Tanzania, Uganda
America
Central America Panama
South America Argentina, Bolivia, Brazil, Colombia, Ecuador, Guyana, French Guyana, Paraguay, Peru, Suriname,
Trinidad and Tobago, Venezuela
Text Box 2. Countries in Africa and the Americas at the risk of yellow fever
The yellow fever endemic countries in the tropical region of Africa and America are shown
in the map (Figure 1) [23]. YF is endemic in ten South and Central American countries and
in several Caribbean islands. Bolivia, Brazil, Colombia, Ecuador, and Peru and Venezuela
are considered to be at greatest risk. Although the disease usually causes only sporadic cases
and small outbreaks, nearly all the major urban centers in the American tropics have been
reinfested with Ae. aegypti and most urban dwellers are vulnerable because of the low im‐
munization coverage. Latin America is now at greater risk of urban epidemics than at any
time in the past 50 years [21].
Figure 1. Yellow fever endemic countries in the tropical regions of Africa and America
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5. The paradoxical absence of yellow fever from Asian countries
YF has never been reported from Asia, but, should it be accidentally imported, the potential
for outbreaks, as the appropriate mosquito vector is present over there [21]. The lack of YFV
in Asia is not clearly understood, although a number of hypotheses have been put forward
[24]. The mosquito vector Ae. aegypti is prevalent in Asia and Pacific countries and has been
important in the rapid emergence of dengue as a major public health problem in the twenti‐
eth century [25]. Laboratory studies indicate that Asian strains of Ae. aegypti can transmit
YFV but are less competent than strains from the Americas. Demographic factors, including
the remote location of sylvatic YF transmission and the cross-protective immunity provided
by prior exposure to dengue and other flaviviruses, likely play a role in the lack of YF in
Asia [26].
6. History of human YF outbreaks
At the beginning of the 20th century, a large number of yellow fever epidemics were record‐
ed in both African and American cities, and these occurred against a background of annual
cases. Table 1 and 2 lists an overview on the historical outbreaks in both tropical Africa and
America by year and countries. Yellow fever epidemics are re-emerging in Africa and Amer‐
ica, and the occurrence of repeated rural outbreaks increases the risk for major urban epi‐
demics. The first disease outbreak that can reliably be regarded as YF was documented in
1648 and occurred in the Yucatan, Mexico and Guadeloupe [27].
Year Countries Name of City Cases Deaths
1668 United States America New York and
Philadelphia
NA NA
1793 United States America NA NA NA
Between 1668 and 1870
nearly 15 epidemics
United States America New York NA In 1798, 1 500 people died
between 1668 and 1867 30
epidemic in 1793
United States America Philadelphia NA 3500
1793 outbreak United States America Philadelphia NA 4000
1853 United States America New Orleans NA 7849
1854 United States America Charleston NA 682 persons
1878 United States America Mississippi Valley NA 13,000 people
1795 outbreak West Indies European troops
stationed there
NA 3 1,000 people died
1905 United States America New Orleans 4000 423
1647 Barbados NA 6000
1802 Haiti NA NA 29000
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Year Countries Name of City Cases Deaths
1878 United States America Over 100 American
towns
NA 20000
1942 Brazil NA NA NA
1981-1982 Bolivia NA NA NA
2003 Colombia States of Cesar,
Magdalena and La
Guajira
28 11
Table 1. The history of Yellow fever outbreaks in subtropical regions of America
7. Recent emergence and resurgence of YF
In the 18th and 19th centuries, YF was a huge public health problem until mosquito control
measures and production of an effective vaccine brought the epidemics under control in the
20th century. Yet as we enter the 21st century this virus is once again a significant public
health problem [15,26,28] and is classified as a reemerging disease. Urban YF has not been
reported from the Americas since 1954, but jungle yellow fever transmitted by Haemagogus
vectors increasingly affects forest dwellers in Bolivia, Brazil, Columbia, Ecuador, and Peru,
and periodically causes small outbreaks [15, 29,30]. The reinvasion of South America by Ae.
aegypti after relaxation of the eradication programme in the 1970s, and presence of Ae. aegyp‐
ti in cities near areas in which sylvatic yellow fever is endemic, poses a threat of urbanisa‐
tion of yellow-fever transmission [25,29]. Following several decades of relative calmness, YF
reappeared in Africa in the 1980s, endangering populations not only in the so-called endem‐
ic countries but in the rest of the world too [31]. The resurgence of YF is also closely connect‐
ed with changes in the modern world and with the interaction of various economic, climatic,
social and political factors [32].
8. Compounding factors for emergence and resurgence of YF
YF has been subjected to partial control for decades, but there are signs that case numbers
are now increasing globally, with the risk of local epidemic outbreaks [33]. The agent of YF,
yellow fever virus, can cause devastating epidemics of potentially fatal, hemorrhagic dis‐
ease. We rely on mass vaccination campaigns to prevent and control these outbreaks. How‐
ever, the risk of major YF epidemics, especially in densely populated, poor urban settings,
both in Africa and South America, has greatly increased due to: (1) reinvasion of urban set‐
tings by the mosquito vector of YF, Ae. aegypti; (2) rapid urbanization, particularly in parts of
Africa, with populations shifting from rural to predominantly urban; and (3) waning immu‐
nization coverage. Consequently, YF is considered an emerging, or reemerging disease of
considerable importance [22].
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Year Countries Number of
cases
Year Countries Number of
cases
1912 Zaire NA 1994 Gabon 28
1917 Zaire NA 1994 Ghana 79
1927-1928 Zaire NA 1994 Kenya 7
1936 Sudan, Uganda, Kenya NA 1994 Nigeria 1227
1940 Sudan, Uganda, Kenya NA 1995 Gabon 16
1958 Zaire NA 1995 Liberia 360
1959 Sudan NA 1995 Senegal 79
1960-1962 Ethiopia 100,000 1995 Kenya 3
1965 Senegal 20,000 1995 Sierra Leone 1
1966 Ethiopia, Sudan 10,000 1996 Benin 120
1969 Nigeria NA 1996 Ghana 27
1971 Angola NA 1996 Senegal 128
1972 Zaire NA 1997 Benin 18
1978 Gambia 8400 1997 Ivory Coast 11
1983 Upper Volta NA 1997 Ghana 6
1988 Angola NA 1997 Nigeria 7
1992-1993 Kenya NA 1997 Liberia 1
Epidemics between
1986 and 1994
Nigeria Approximately
120,000
1998 Burkina Faso 2
1990 Cameroon 20,000 2000 Nigeria 2
1992 Kenya NA 2000 Liberia 102
1993 Ghana 39 2000 Guinea 512
1993 Kenya 27 2001 Ivory Coast 203
1993 Nigeria 152 2001 Guinea 18
1994 Cameroon 10 2005 Sudan 491
Table 2. The history of Yellow fever outbreaks in the subtropical regions of Africa
8.1. Unchecked and unplanned urbanization
It is one of the key determinant in terms emergence and resurgence of many vector-borne diseas‐
es particularly YF. With an annual growth rate of nearly 4%, Africa’s cities are the fastest expand‐
ing in the world. Not only are more and more people living in the cities but the number of cities is
also increasing. Whereas today 62.1% of Africa’s population lives in rural areas, it is predicted
that by 2020 this proportion will be reversed, i.e. that 63% of the continent’s population will be
urban dwellers. Between now and 2015, it is estimated that the number of cities with more than 1
million inhabitants will increase from 43 to 70 in Africa [34]. On the edge of modern cities, shanty
towns with no access to basic sanitation (running water and waste disposal) are also developing
rapidly. Domestic water containers and all manner of refuse littering the streets (aluminium and
tin cans, old tyres, etc.) favor the multiplication of breeding sites for mosquito larvae [35].
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8.2. Climate change
Climate change affects the spread of vector borne diseases both directly and indirectly. Global
warming and increased rainfall contribute to the abundance and distribution of vectors like
mosquitoes. Current evidence suggests that inter-annual and inter-decadal climate variability
have a direct influence on the epidemiology of vector-borne diseases [36]. It is estimated that
average global temperatures will have risen by 1.0-3.5oC by 2100 [37], increasing the likelihood
of many vector-borne diseases [36]. If the water temperature rises, the larvae take a shorter time
to mature [38] and consequently there is a greater capacity to produce more offspring during the
transmission period.
The extrinsic incubation period of dengue and yellow fever viruses is also dependent on
temperature. Within a wide range of temperature, the warmer the ambient temperature, the
shorter the incubation period from the time the mosquito imbibes the infective blood until
the mosquito is able to transmit by bite. The implication is that with warmer temperatures
not only would there be a wider distribution of Ae. aegypti and faster mosquito metamor‐
phosis, but also the viruses of dengue and yellow fever would have a shorter extrinsic incu‐
bation period and thus would cycle more rapidly within the mosquito. A more rapid cycle
would increase the speed of epidemic spread [39].
8.3. Globalization
Kelley Lee (2000) [40] has defined globalization as ‘the process of closer interaction of human ac‐
tivity across a range of spheres, including the economic, social, political and cultural, experi‐
enced along three dimensions: spatial, temporal and cognitive’. The recent emergence and
resurgence of vector-borne diseases are the result of human activities-transportation of goods
and people-and will continue with increasing globalization of trade [41]. The increasing phe‐
nomenon of globalization has been observed to alter the YF disease pattern.
8.4. International travel and trade
Every year, about 9 million people from Asia, Europe, and North America travel to countries
where yellow fever is endemic; the number of travellers who actually visit areas within these
countries where transmission of the virus occurs might exceed 3 million in the coming years [42].
In Africa yellow fever was mainly a problem of the sub-Saharan countries of West Africa, but
reached as far east as central Sudan and Kenya [43-46]. A large number of outbreaks were report‐
ed in eastern Mexico and other Central American countries. At this time, YF was an epidemic
disease mainly of port cities [35].
8.5. Rural-urban migration
West Africa is witnessing significant migratory flows owing to rural exodus, movements of
religious groups such as the Mourides in Senegal, cross-border movements of seasonal
workers and nomadic pastoral communities, trade routes stretching from the Sahel to the
coast of the Gulf of Guinea, the phenomenon of new urban dwellers returning regularly to
their rural communities of origin, and migration by populations fleeing armed conflicts.
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These human movements increase the risk of contamination of non-immune persons travel‐
ling in areas where contaminated vectors persist and, conversely, favour the introduction of
the disease into previously YF free zones [47].
8.6. Genetic and behavioral variation
YF outbreaks are common in Africa despite the current knowledge of the disease transmis‐
sion and the availability of a vaccine. In Africa, YF cases are not uniformly distributed
throughout the endemic area; rather, more cases are reported in West Africa compared to
East and Central Africa. Genetic differences between genotypes of YF in Africa probably
contribute to the observed distribution of YF outbreaks. Genetic and behavioral variation in
mosquito vectors may also play a major role in the distribution of YF outbreaks. The other
factors also contribute to the epidemiology of YF, including host genetic background, cli‐
mate, vaccination coverage, vertebrate hosts and movement of vertebrate hosts [48].
9. Yellow fever vectors
Yellow fever virus is transmitted principally by insects (mosquitoes), but ticks (Amblyomma
variegatum) may play a secondary and minor role in Africa. It was not until 1901 that yellow
fever transmission to humans was associated with the blood-feeding by the Ae. aegypti mos‐
quito (Figure 2), which was a major breakthrough in understanding this dreadful disease.
Dispatched to Cuba by the United States government to investigate the cause of YF, Walter
Reed and colleagues confirmed that the primary mode of YF transmission to humans was
the Ae. aegypti mosquito (Figure 2) and the in ground-breaking virologic studies demonstrat‐
ed that the disease was caused by an agent that could be filtered from the blood of infected
individuals [49]. The reservoirof yellow fever virus is the susceptible vector mosquito spe‐
cies that remains infected throughout its life and can transmit the virus transovarially. Yel‐
low fever can persist as a zoonosis in the tropical areas of Africa and America, with
nonhuman primates responsible for maintaining the infection. Man and monkey play the
role of amplifiers of the amount of virus available for the infection of mosquitos [50].
Figure 2. Aedes aegypti, the primary disease vector for yellow fever (Photo by Muhammad Mahdi Kharim, published
under the GNU free documentation licences)
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10. Yellow fever virus
Ever since the causative agent of YF disease YFV, was first isolated in 1927 from a Ghanaian
patient named Asibi [50], the Asibi YFV strain is still widely used by the scientists of today.
YFV is the prototype member of the family Flaviviridae(from the Latin flavus, meaning yel‐
low), and genus Flavivirus, which get their name from the Latin word for yellow (flavus).
The genome is a single-stranded, positive-sense RNA, 10,500 - 11,000 nucleotides in length.
The genus Flavivirus contains approximately 70 viruses, and the major flavivirus diseases
are yellow fever (YF), dengue, West Nile, Japanese encephalitis, and tick-borne encephalitis
[51]. Unlike other mosquito-borne flaviviruses, YFV has a tropism for the liver and causes a
viscerotropic disease whereas many other mosquito-borne flaviviruses have a tropism for
the brain, or in the case of the DEN viruses they target cells of reticuloendothelial origin [52].
It was one of the earliest viruses to be identified and linked to human disease. Although
substantial variation exists among strains, they can be grouped into monophyletic geo‐
graphical variants, called topotypes. African isolates are usually grouped into two topo‐
types, associated with East and West Africa [53,54], although some studies have argued for
up to five [55]. Two more have been identified from South America, although one has not
been recovered since 1974, suggesting that it may be extinct in the wild. There is no evidence
for a difference in virulence between the topotypes [56]. YF activity often occurs in areas af‐
ter increases in temperature and rainfall that will favor increased biodiversity, including in‐
creased numbers of animals and arthropods while reduced rainfall limits mosquito vector
density [49]. It has been known for over 50 years that increased temperatures are associated
with enhanced transmission of YF virus [56] due to shortened extrinsic incubation period
and increased biting by mosquitoes of vertebrate hosts [49].
11. Epidemiology
The virus is maintained in endemic areas of Africa and South America by enzootic transmis‐
sion between mosquitoes and monkeys, and obviously the epidemiology of the disease re‐
flects the geographical distribution of the mosquito vectors [57].
11.1. Transmission
The enzootic transmission cycle involves tree-hole-breeding mosquitoes such as Aemagogus
janthinomys(South America) and Ae. africanus(Africa), and nonhuman primates. Infection of
mosquitoes begins after ingestion of blood containing a threshold concentration of virus
(~3.5 log 10 ml¯1), resulting in infection of the midgut epithelium. The virus is released from
the midgut into the hemolymph and spreads to other tissues, notably the reproductive tract
and salivary glands. A period of 7-10 days is required between ingestion of virus and virus
secretion in saliva (the extrinsic incubation period), after which the female mosquito is capa‐
ble of transmitting virus to a susceptible host.
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Vertical transmission of virus occurs from the female mosquito to her progeny and from
congenitally infected males to females during copulation. Virus in the egg stage provides a
mechanism for virus survival over the dry season when adult mosquito activity and hori‐
zontal transmission abate. The virus is maintained over the dry season by vertical transmis‐
sion in mosquitoes. Ova containing virus survive in dry tree-holes and hatch infectious
progeny mosquitoes when the rains resume [58].
Figure 3. Yellow Fever Transmision cycles in Africa and South America
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11.2. Transmission cycle patterns and ecology
In Africa, three transmission cycles can be distinguished: the sylvatic,  urban, and savan‐
nah cycles. In South America, only sylvatic and urban cycles have been identified (Figure
3). In all the three cycles, yellow fever virus is transmitted between primates by diurnally
active tree hole-breeding mosquitoes. Neither the virus nor the clinical disease differs in
these three cycles, but identifying the type of transmission cycle is important for disease
control. In all of these cycles, endemic and epidemic disease patterns can occur [59]. Syl‐
vatic yellow fever (YF) in South America is maintained in an epizootic cycle between non-
human primates  and Haemagogus  and Sabethes  mosquitoes,  tree-hole  breeding  species
that  reside  in  the  forest  canopy.  Humans  are  infected  incidentally  in  the  sylvatic  cycle
when they inhabit or work in the forest where infected mosquitoes are present [60].
In the ‘‘Jungle’’ or ‘‘Sylvatic’’ cycle, the virus is transmitted among monkeys by tree-hole
breeding mosquitoes.  Humans are  infected incidentally  when entering the  area  (e.g.,  to
work as foresters) and have what is termed ‘‘jungle yellow fever’’. The main vector in Af‐
rica is Aedes africanus, while in South America it is Haemagogus species. Other mosquito
species involved in transmission include Ae. africanus, Ae. furcifer, Ae. vittatus, Ae. luteoce‐
phalus,  Ae.  opok,  Ae.  metallicus,  and  Ae.  simpsoni  in  Africa,  and  Sabetheschloropterus  in
South America. The primate species acting as vertebrate hosts of the virus also differ by
geographic area.
The ‘‘Urban’’  cycle involves transmission of  YF virus between humans by Ae.  aegypti,  a
domestic vector that breeds close to human habitation in water, and scrap containers in‐
cluding used tires in urban areas or dry savannah areas.  In this situation, the disease is
known as ‘‘urban yellow fever’’ [49]. YF is transmitted in urban cycles between humans
and the container-breeding, anthropophilic mosquito Aedes aegypti  [15]. In Africa, a third
cycle is recognized, the intermediate or savannah cycle, where humans in the moist savan‐
nah  regions  come  into  contact  with  the  jungle  cycle.  This  has  been  referred  to  as  the
‘‘Zone of  Emergence.’’  Although YF is  considered to  be a  mosquito-borne disease,  Am‐
blyommavariegatum ticks have been shown to be naturally infected with the virus in cen‐
tral Africa [61]. The significance of this observation in the ecology of YF virus has yet to
be determined.
Urban  cycle  epidemics  develop  from  anthroponotic,  also  known  as  human-to-human,
transmission in which humans serve as the sole host reservoir of the peridomestic Ae. ae‐
gypti  mosquito  vector.  Urban  epidemics  occur  when  anicteric  but  viremic  persons  who
are not yet severely ill, travel from jungles and savannas to cities where they infect local
Ae. aegypti mosquitoes, a species that is abundant in urban areas and in areas where hu‐
mans  store  water.  When  YF  is  identified  in  any  setting,  the  likelihood  that  it  resulted
from  human-to-human  transmission  or  its  possible  introduction  into  an  urban  setting
must be rapidly assessed to determine the need for emergency vaccination [62].  The in‐
trinsic incubation period in human beings is between two and six days. The extrinsic in‐
cubation period in  a  mosquito  varies  from four  to  18  days  (average 12  days),  with  the
temperature  and humidity.  Once  the  mosquito  becomes  infective,  it  remains  so  for  the
rest of its life [63].
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12. Clinical signs and symptoms
YF is the original viral haemorrhagic fever (VHF), a pansystemic viral sepsis with viraemia,
fever, prostration, hepatic, renal, and myocardial injury, haemorrhage, shock, and high le‐
thality. Patients with yellow fever suffer with a terrifying and untreatable a clinical disease
as yellow fever is responsible for 1000-fold more illness and death than Ebola. Yellow fever
stands apart from Ebola and other VHFs in its severity of hepatic injury and the universal
appearance of jaundice [10]. It is difficult to distinguish YF' clinically from many other tropi‐
cal diseases and often impossible when the condition is mild or atypical. The clinical symp‐
toms associated with the early stages of YF infection are indistinguishable from those of
malaria, and where the two diseases coexist, YF should not be ruled out even in the absence
of jaundice or the finding of malaria parasites in a blood smear [64,65]. The clinical disease
varies from non-specific abortive illness to fatal haemorrhagic fever [66]. Disease onset is
typically abrupt, with fever, chills, malaise, headache, lower back pain, generalised myalgia,
nausea, and dizziness. On physical examination the patient is febrile and appears acutely ill,
with congestion of the conjunctivae and face and a relative bradycardia with respect to the
height of fever (Faget’s sign). The average fever is 39o C and lasts for 3.3 days.
13. Diagnosis of YF
Clinical diagnosis of yellow fever is possible when the pathognomonic features of biphasic/
triphasic acute illness and typical clinical features occur in unvaccinated individuals with a
compatible exposure history. Unfortunately, these features are present only in a minority of
patients [67]. Laboratory confirmation of YF is pivotal to diagnosis, but unfortunately re‐
quires highly trained laboratory staff with access to specialized equipment and materials.
Laboratory diagnosis of YF is made by detection of either virus or virus antigen or genome
(by enzymelinkedimmunosorbent assay (ELISA), polymerase chain reaction (PCR), or inoc‐
ulation virus into suckling mice, mosquitoes, or cell cultures), or by serology (immunoglo‐
bulin M capture ELISA), though cross-reactions with other flaviviruses complicate serologic
methods of diagnosis. Postmortem examination of the liver reveals pathognomonic features
of YF, including mid-zonal necrosis, and definitive diagnosis can be made by immunohisto‐
chemical staining of tissues (liver, heart, kidneys) for yellow fever antigen. It is important to
note that liver biopsy should never be used for diagnosis during YF illness because of the
risk for fatal hemorrhage at the biopsy site [67].
14. Treatment
In the absence of specific therapy, treatment of YF is chiefly supportive. Because most YF
cases occur in areas lacking basic hospital facilities and where patients do not have access to
modern intensive care. In the early stages of the disease, therapy should focus on controlling
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the fever and vomiting, relieving the headache and abdominal pains, and correcting the de‐
hydration. During the hepatorenal phase, suitable therapy based on careful patient monitor‐
ing should be administered to control the bleeding and manifestations associated with
hepatorenal damage. Appropriate treatment to control malaria and secondary bacterial in‐
fections should be administered when necessary [64,65].
15. Prevention and control
Because no antiviral treatment exists for the disease, prevention through use of personal
protection measures and vaccination is crucial to lower disease risk and mortality [14]. A
number of approaches have been taken to control YF. Historically, the development of live
vaccines was used to control the disease in Africa, whereas mosquito vector control was
used in the Americas. Following the demonstration that YFV is transmitted by Ae. aegypti
came the realization that it should be possible to control the disease by controlling mosquito
populations [26]. The re-emergence of yellow fever in Africa and South America during the
past decade tempers previous optimism that this disease as a public health problem could
be eliminated during the twentieth century [15]. Vaccination and eradication of Ae. aegypti
are the only effective strategies to reduce YF morbidity and mortality in the affected areas.
15.1. Yellow fever vaccine
Yellow fever vaccine is given for two reasons: to protect travellers visiting areas with the
risk of yellow fever virus transmission and to prevent the international spread by minimiz‐
ing the risk of importation and translocation of the virus by viraemictravellers [14]. Follow‐
ing the successful isolation of YFV in 1927 by American (strain Asibi) and French (strain
French viscerotropic virus) workers, researchers placed great effort on the development of
vaccines. The development of two live vaccines in the 1930s represents a milestone in the
control of the disease. Strain Asibi was passaged through chicken tissue to develop the 17D
vaccine strain, whereas strain French viscerotropic virus was passaged through mouse brain
to develop the French neurotropic vaccine (FNV). Both vaccines are highly efficacious and
they dramatically reduced the number of YF cases in Africa. Unfortunately, the FNV caused
cases of postvaccinal neurotropic disease in vaccinees and was discontinued in 1971, where‐
as 17D is still used today throughout the world [26].
Although immunity from vaccination probably lasts for a lifetime [68,69], a 10 year interval
between vaccinations is stipulated in the International Health Regulations (2005) for individ‐
uals travelling to countries with a yellow fever vaccination entry requirement. The Interna‐
tional Certificate of Vaccination or Prophylaxis is a traveler’s official documentation and it
becomes valid 10 days after vaccination and remains so for 10 years [36]. Re-immunization
is required every 10 years to maintain a valid international vaccination certificate. The
World Health Organization recommends vaccination of children at 9 months old, concomi‐
tant with measles vaccination, because of better cost/benefit analysis than campaign vaccina‐
tions to control outbreaks [70]. It is recommended that the yellow fever vaccine be
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administered at 12 months of age. In the case of outbreaks, it can be administered as early as
6 months of age [71]. Yellow fever vaccine is a live vaccine, so theoretically it should not be
given to pregnant women or to immunosuppressed individuals. A single fatal adverse reac‐
tion (encephalitis) has been reported in an immunosuppressed individual with HIV/AIDS.
15.2. Vector control
Vector control is defined as measures of any kind directed against a vector of disease and
intended to limit its ability to transmit the disease [72]. In yellow fever control specifically in
certain circumstances, mosquito control is vital until vaccination takes effect.
15.2.1. Source reduction
The risk of yellow fever transmission in urban areas can be reduced by eliminating potential
mosquito breeding sites and applying insecticides to water where they develop in their im‐
mature stages [13]. Indeed, source reduction is one of the key components in the vector con‐
trol programme since the target is exceptionally specific unlike adult control [73]. Vector-
control strategies that were once successful for elimination of yellow fever from many
regions have faltered, leading to reemergence of the disease[3]. Application of spray insecti‐
cides to kill adult mosquitoes during urban epidemics, combined with emergency vaccina‐
tion campaigns, can reduce or halt yellow fever transmission and the "buying time" for
vaccinated populations to build immunity [13].
Historically, mosquito control campaigns successfully eliminated Ae. aegypti, the urban yel‐
low fever vector, from most mainland countries of central and South America. However,
this mosquito species has re-colonized urban areas in the region and poses a renewed risk of
urban yellow fever. Mosquito control programmes targeting wild mosquitoes in forested
areas are not practical for preventing jungle (or sylvatic) yellow fever transmission [13]. The
period between about 1950 and the 1970s was one of the complacency about the control of
YF, probably arising from the feeling that YF vaccination had solved the problem. Ae. aegypti
control was reduced and overall disease record keeping appears to have diminished. For the
period 1960–2005, only 110 yellow fever points were recorded in Africa and 171 in South
America. In both regions, these records more or less fall within the same areas of risk shown
for the first half of the last century, although there is a noticeable lack of new records in Cen‐
tral America and proportionately more cases within the Amazon basin [33].
15.2.2. Insect repellents
Ae. aegypti, has adapted their peak biting activities in the early evening and early morning,
when their potential hosts are less protected. Mosquito repellents have a unique role under
these conditions. Easily accessible, safe and effective mosquito repellents provide a valuable
supplement to IRS and ITN use, and in areas with day-biting, exophagic vectors, this may be
the only option for reducing the level of disease transmission [74]. The core principle of re‐
pellents usage is that they are extremely useful and helpful whenever and wherever other
personal protection measures are impossible or impracticable [75]. Insect repellents are ex‐
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ceptionally helpful to the travelers, who visit for a short-span of time in the disease endemic
areas. The main advantage is that the repellents are relatively cheap, highly effective and
can be applied as a short-term measure [76].
A laboratory study was carried out to evaluate the relative efficacy of N-N-diethylm-tolua‐
mide (DEET) and N,N-diethyl-phenylacetamide (DEPA)-treated wristbands against three
major vector mosquitoes. Overall, both DEET and DEPA have shown various degrees of re‐
pellency impact against all three vector mosquitoes. DEPA treated wristbands did not show
any significant differences in terms of reduction in human landing rate and the mean com‐
plete protection time against An. stephensi and Ae. aegypti were between 1.5 and 2.0 mg/cm2
[77]. A study revealed the repellent efficacy of dimethyl-phthalate (DMP) treated wristband
against Ae. aegypti under the laboratory conditions. It is estimated that 74.4 and 86.5% of re‐
duction of man landing rates were obtained against Ae. aegypti at concentrations of 1.5 and
2.0 mg/cm2 respectively [1]. These studies results suggest that repellent-treated fabric strips
could serve as a means of potential personal protection expedient to avoid insect’s annoy‐
ance and to reduce vector-borne disease transmission.
However, generally synthetic repellents have several limitations, including reduced efficacy
owing to sweating, unpleasant odor, relatively expensive and can cause allergic reactions
[72]. Plants have been used since ancient times to repel/kill blood-sucking insects in the hu‐
man history and even now, in many parts of the world, people use plant substances to
drive-away the mosquitoes and other blood-sucking insects [78]. Currently repellents of
plant origin have been receiving massive attention due to their environmental and user
friendly nature [79].
It is unlikely that vector control strategies alone will result in the elimination of yellow fe‐
ver; such strategies must be combined with effective vaccination programs. Besides, in YF
endemic countries, people particularly travelers should take precautions to avoid mosqui‐
to bites to reduce the risk of  yellow fever.  Besides,  using insect  repellents,  people must
use  permethrin-impregnated  clothing,  and  bed  nets  and  staying  in  the  screened  room
could be advisable.
16. Conclusion
YF has played a central role in the history of infectious diseases. It was the first disease to be
demonstrated to be transmitted by an arthropod, one of the first diseases to be shown to be
caused by a virus, and one of the first infectious agents to be controlled by the development
of a live vaccine [80]. Indeed, the challenges and dangers posed by yellow fever remain for‐
midable. It is mainly contributed by the global warming, land use changes, uncontrolled
population growth, unchecked urbanization, rural - urban migration, international trade,
conflict and civil disruption. Although the tools for diagnosis, vector control, vaccine and
surveillance are available, their implementation is extremely poor or inadequate in many of
the resource-constrained YF endemic countries. In addition, the global-warming concomi‐
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tant effect immensely contributed to the high reproduction rate and the capacity of insect
vectors to establish and to adapt to new environmental conditions.
Certainly, the present scrutiny clearly suggests that the yellow fever encephalitis is emerg‐
ing and resurging as a global public health threat in a changing environment. It contributes
to remain as a disease of increasing epidemic risk. Therefore, the following issues such as
high population density, development of peri-urban areas with rural interfaces, urban con‐
struction in forest areas, inconsistent vector control programme, spread of new pathogens,
inadequate coverage and short-supply of yellow fever vaccine, must be addressed effective‐
ly for the betterment of humankind, eventually to build a yellow fever free world in the near
future.
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